{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:55:53Z","timestamp":1793310953115,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.urolonc.2024.05.010","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T11:38:46Z","timestamp":1719315526000},"page":"331.e13-331.e24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC)"],"prefix":"10.1016","volume":"42","author":[{"given":"Sara","family":"Custodio-Cabello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilma","family":"Pacheco-Barcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Palka-Kotlowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fern\u00e1ndez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Fern\u00e1ndez","family":"Del \u00c1lamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Oliveros-Acebes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-3626","authenticated-orcid":false,"given":"Luis","family":"Cabez\u00f3n-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2024.05.010_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca Cancer J Clin"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0002","series-title":"Prostate cancer (Internet)","article-title":"The epidemiology of prostate cancer","author":"Giona","year":"2021"},{"issue":"16","key":"10.1016\/j.urolonc.2024.05.010_bib0003","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1200\/JCO.19.02808","article-title":"Risk of prostate cancer associated with familial and hereditary cancer syndromes","volume":"38","author":"Beebe-Dimmer","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0004","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1158\/1055-9965.EPI-16-1046","article-title":"Practical consortium. A review of prostate cancer genome wide association studies (GWAS)","volume":"27","author":"Benafit","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.1016\/j.urolonc.2024.05.010_bib0005","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.urolonc.2024.05.010_bib0006","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.010_bib0007","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2017.02.023","article-title":"Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer","volume":"72","author":"Annala","year":"2017","journal-title":"Eu Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.05.010_bib0008","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eururo.2018.01.035","article-title":"Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide","volume":"74","author":"Antonarakis","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0009","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.20.00046","article-title":"Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019","volume":"38","author":"Giri","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.urolonc.2024.05.010_bib0010","first-page":"2240","article-title":"Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer","volume":"35","author":"Darst","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.urolonc.2024.05.010_bib0011","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0012","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/pros.23739","article-title":"Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing","volume":"79","author":"Giri","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0013","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: A prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0014","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41391-021-00397-2","article-title":"Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer","volume":"25","author":"Martinez Chanza","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.urolonc.2024.05.010_bib0015","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.eururo.2021.09.029","article-title":"Association of inherited mutations in DNA repair genes with localized prostate cancer","volume":"81","author":"Lee","year":"2021","journal-title":"Eur UroL"},{"issue":"6","key":"10.1016\/j.urolonc.2024.05.010_bib0016","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J. Clin Oncol."},{"key":"10.1016\/j.urolonc.2024.05.010_bib0017","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1200\/PO.19.00346","article-title":"Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations","volume":"4","author":"Mota","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0018","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0019","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2018.09.048","article-title":"Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency","volume":"751","author":"Zafeiriou","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0020","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0021","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a brca1 or brca2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0022","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.eururo.2020.09.024","article-title":"Efficacy of PARP inhibition in metastatic castration-resistant prostate cancer is very different with non-brca DNA repair alterations: Reconstructing prespecified endopoints for cohort b prom the phase 3 profound trial of Olaparib","volume":"79","author":"Stopsack","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0023","first-page":"1","article-title":"Abiraterone and Olaparib for metastatic castration resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0024","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2024.05.010_bib0025","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.3390\/cancers14122950","article-title":"The homologous recombination deficiency scar in advanced cancer: Agnostic targeting of damaged DNA repair","volume":"14","author":"Pacheco-Barcia","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0026","article-title":"Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer","volume":"5","author":"Taza","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2024.05.010_bib0027","doi-asserted-by":"crossref","first-page":"TPS221","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS221","article-title":"Talapro-3: A phase 3, double-blind, randomized study of enzalutamide plus talazoparib versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)","volume":"40","author":"Agarwal","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2024.05.010_bib0028","volume":"39","author":"Dana","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0029","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"7","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0030","unstructured":"Schaeffer EM et al. NCCN Guidelines Insights: Prostate cancer. Version 1.2023: Featured updates to the NCCN guidelines. J. Natl. Compr. Canc. Netw. 20,1288\u20131298."},{"key":"10.1016\/j.urolonc.2024.05.010_bib0031","doi-asserted-by":"crossref","first-page":"8940","DOI":"10.3390\/ijms24108940","article-title":"Multi-gene next-generation sequencing panel for analysis of BRCA1\/BRCA2 and homologous recombination repair genes alterations metastatic castration-resistant prostate cancer","volume":"24","author":"Maluberti","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.010_bib0032","doi-asserted-by":"crossref","first-page":"19135","DOI":"10.1038\/s41598-023-46323-5","article-title":"Impact of germline DNA repair gene variants on prognosis and treatment of men with advanced prostate cancer","volume":"13","author":"Hansen","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0033","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41416-022-01915-2","article-title":"Prognostic significance of pathogenic variants in BRCA2, BRCA2, ATM and PALB2 in men undergoing hormonal therapy for advanced prostate cancer","volume":"127","author":"Kimura","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0034","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1158\/1078-0432.CCR-20-0168","article-title":"Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer","volume":"26","author":"Stopsack","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0035","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.05.010_bib0036","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clgc.2022.06.016","article-title":"The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone sensitive prostate cancer","volume":"20","author":"Lee","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.05.010_bib0037","doi-asserted-by":"crossref","unstructured":"Wu Y, et al. Rare germline pathogenic mutations of DNA repair genes are most strongly associated with grade group 5 prostate cancer. Eur. Urol. Oncol. 3, 224\u2013230.","DOI":"10.1016\/j.euo.2019.12.003"},{"issue":"11","key":"10.1016\/j.urolonc.2024.05.010_bib0038","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/jamaoncol.2023.3482","article-title":"Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer","volume":"9","author":"Darst","year":"2023","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2024.05.010_bib0039","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.010_bib0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.clgc.2017.08.006","article-title":"Characterization of differences between prostate cancer patients presenting with de novo versus primary progressive metastatic disease","volume":"16","author":"Finianos","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"10.1016\/j.urolonc.2024.05.010_bib0041","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/pros.24135","article-title":"Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer","volume":"81","author":"Nizialek","year":"2021","journal-title":"Prostate"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392400468X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392400468X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:46:21Z","timestamp":1737632781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392400468X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S107814392400468X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.05.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC)","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}